Qualitative analysis of repaired filtering blebs with anterior segment-optical coherence tomography

Cerdà-Ibáñez, M.; Pérez-Torregrosa, V.T.; Olate-Pérez, Á.; Palacios, I. Almor; Gargallo-Benedicto, A.; Osorio-Alayo, V.; Rego, A. Barreiro; Duch-Samper, A.

doi:10.1016/j.oftale.2017.03.014

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that the so-called cystoid-type blebs (characterized by the presence of multiple small cysts inside the bleb) were related to a higher probability of success compared with other filtering blebs presenting less cystic spaces. This is in accordance with other studies [28,29].…”

Section: Discussionsupporting

confidence: 94%

Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

Rodríguez-Calvo

Rodríguez-Uña

Fernández-Vega-Cueto

et al. 2023

JCM

View full text Add to dashboard Cite

Background: The purpose of this study is to evaluate the utility and safety of plasma rich in growth factors immunosafe eye drops (is-ePRGF) in the postoperative treatment of non-penetrating deep sclerectomy (NPDS). Methods: This is a case–control study in patients with open-angle glaucoma. Group one (control) was not treated with is-ePRGF, while group two (is-ePRGF) was treated (four times a day for four months). Postoperative evaluations were performed at one day, one month, three months and six months. The main outcomes were: intraocular pressure (IOP), microcysts in blebs with AS-OCT and the number of hypotensive eye drops. Results: Preoperatively, group one (n = 48 eyes) and group two (n = 47 eyes) were similar in age (71.5 ± 10.7 vs. 70.9 ± 10.0 years; p = 0.68), IOP (20.6 ± 10.2 vs. 23.0 ± 9.0 mmHg; p = 0.26) and number of hypotensive drugs (2.7 ± 0.8 vs. 2.8 ± 0.9; p = 0.40). The IOP at six months dropped to 15.0 ± 8.0 mmHg (IOP reduction: −27.2%) and 10.9 ± 4.3 mmHg (IOP reduction: −52.6%) for group one and group two, respectively (p < 0.01). At six months, blebs with microcysts were 62.5% (group one) and 76.7% (group two). Postoperative complications were observed in 12 eyes (25%) for group one and in 5 eyes (11%) for group two (p = 0.06). No specific complications related to the use of is-ePRGF were identified. Conclusions: Topical is-ePRGF seems to reduce IOP and the rate of complications in the medium term after NPDS, so it can be considered as a possible safe adjuvant to achieve surgical success.

show abstract

Section: Discussionsupporting

confidence: 94%